Now New and Improved! Watch CityNews Winnipeg, and get up-to-the-minute breaking-news alerts, traffic, weather and video from ...
The WATER IV AS trial aims to assess Aquablation as earlier intervention for men on active surveillance Procept BioRobotics has received a second FDA investigational device exemption (IDE) to allow ...
Siemens Healthineers’ MRI scanners would guide robotic neurosurgeries performed with AiM’s platform. Elsewhere, Procept ...
The breakthrough at Columbia University lays the groundwork for future clinical studies aimed at developing new treatments.
Only men with a dangerous genetic variant and a family history of cancer should be offered screening, say UK advisors.
Abhinav Sidana, MD, a urologic oncologist at the University of Chicago Medicine (UChicago Medicine), has performed the first ...
Procept BioRobotics (Nasdaq:PRCT) announced that it received FDA investigational device exemption (IDE) for a second ...
PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...
Olympus said Tuesday it has agreed to buy Israel-based BioProtect for $270 million to expand its product portfolio in ...
Olympus has signed a definitive agreement to acquire BioProtect for $270 million, adding biodegradable balloon spacer ...
Medical Device Network on MSN
Olympus agrees $270m BioProtect buyout to expand prostate cancer offerings
BioProtect’s lead product is a spacer system designed to protect healthy tissues during radiation therapies for prostate ...
The Spring device for treating BPH [Image courtesy of Zenflow] Zenflow recently shared data from its BREEZE pivotal clinical trial supporting the use of its Spring implant for benign prostatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results